Dr. Pardee on CPI-613 for Patients With R/R AML

Timothy S. Pardee, MD
Published Online: Thursday, Sep 11, 2014

Timothy S. Pardee, MD, assistant professor, Hematology & Oncology, Wake Forest University Baptist Medical Center, discusses the results of a phase I study of the mitochondrial metabolism inhibitor CPI-613 for relapsed or refractory acute myeloid leukemia (AML).

Twenty four patents with relapse or refractory AML received this agent in combination with high-dose cytarabine and mitoxantrone. The response rate was 54% (11 complete remissions and 2 complete remissions with incomplete count recovery).

Pardee says that, typically, patients with poor risk cytogenetics tend to respond poorly to chemotherapy. On this trial, the response rate of patients with poor risk cytogenetics was 53%.

Timothy S. Pardee, MD, assistant professor, Hematology & Oncology, Wake Forest University Baptist Medical Center, discusses the results of a phase I study of the mitochondrial metabolism inhibitor CPI-613 for relapsed or refractory acute myeloid leukemia (AML).

Twenty four patents with relapse or refractory AML received this agent in combination with high-dose cytarabine and mitoxantrone. The response rate was 54% (11 complete remissions and 2 complete remissions with incomplete count recovery).

Pardee says that, typically, patients with poor risk cytogenetics tend to respond poorly to chemotherapy. On this trial, the response rate of patients with poor risk cytogenetics was 53%.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x